Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Influence of Hypoxia Inducible Factors on the Immune Microenvironment in Ovarian Cancer

MARKUS DUECHLER, LUKASZ PECZEK, MARIA SZUBERT and JACEK SUZIN
Anticancer Research June 2014, 34 (6) 2811-2819;
MARKUS DUECHLER
1Department of Bioorganic Chemistry, Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Lodz, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mduchler{at}cbmm.lodz.pl
LUKASZ PECZEK
1Department of Bioorganic Chemistry, Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Lodz, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIA SZUBERT
2Department of Gynaecology and Obstetrics of the Medical University of Lodz, Clinical Department of Operative and Oncological Gynaecology, Lodz, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JACEK SUZIN
2Department of Gynaecology and Obstetrics of the Medical University of Lodz, Clinical Department of Operative and Oncological Gynaecology, Lodz, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Ovarian tumors remain immunogenic even at advanced stages, but cancer-induced immunosuppression abrogates immune surveillance. The composition of the immune microenvironment in ovarian tumors was characterized by analyzing selected immunosuppressive factors in specimens from cancer patients. The influence of the hypoxia inducible factors on the immune microenvironment was also addressed. Materials and Methods: Tumor tissue was collected from 21 ovarian cancer patients immediately following tumor excision during surgery. The mRNA expression of selected genes was quantified, and tumor infiltrating leukocytes were characterized by flow cytometry to identify regulatory T-cells, myeloid-derived suppressor cells, and type-2 macrophages. Results: Overall, a pronounced heterogeneity was found among the analyzed samples. Nevertheless, statistical analysis revealed that the expression of hypoxia inducible factors correlated with the transcription levels of several immunosuppressive molecules. Conclusion: The activity of hypoxia inducible factors contributes to cancer immunosuppression in ovarian cancer patients.

  • Cancer immunosuppression
  • cancer hypoxia
  • human ovarian cancer
  • immune microenvironment
  • surgical specimen

Ovarian cancer accounts for approximately 4% of newly-diagnosed cancers in women. Despite recent progress in diagnosis and treatment, ovarian cancer still is responsible for about 5% of female deaths caused by malignant neoplasms (1). The 5-year survival rate of surgery followed by chemotherapy is below 50% (1, 2). This rather bad prognosis is mainly the consequence of late diagnosis – usually in advanced III/IV clinical stage – due to lack of initial symptoms. Moreover, intrinsic and acquired drug resistance induces a high relapse rate.

For some time, ovarian cancer was not considered highly immunogenic. The apparent lack of immunogenicity was explained by the clonal evolution of cancer cells resulting in cells devoid of immune-stimulating antigens (3). Meanwhile it became clear, that ovarian tumors remain immunogenic at advanced stages, and that it is the cancer-induced immunosuppression which mainly controls immune escape (4, 5). As more evidence is accumulating for an activated but suppressed immune response in ovarian cancer, therapies aiming at re-activation of an anticancer immune response gain attention as alternative or complementary treatment options (6).

Anticancer immunity is shut-down through direct cell-cell interactions between cancer cells and leukocytes and through soluble factors, altogether establishing an immunosuppressive environment for unimpeded cancer growth. There, the maturation of myeloid cells is inhibited while the development of regulatory T (T-reg)-cells is favoured. T-reg cells very efficiently block anticancer immune reactions (7) and the levels of T-reg cells in the peripheral blood of ovarian cancer patients have been correlated with disease relapse and poor prognosis (8, 9). The conversion of naive T-cells into T-reg cells is either promoted directly by tumor cells or by other suppressor cells which are attracted and instructed by the tumor. A major population among these tumor-associated immunosuppressive cells are myeloid-derived suppressor cells (MDSC) which include several sub-types like myeloid progenitor cells, immature dendritic cells and granulocytes (10, 11). Also macrophages are converted from an M1 type, capable of lysing tumor cells and presenting tumor-associated antigens, into M2-type suppressor cells, which exert tumor supportive activities promoting invasion and metastasis (12).

Accumulating evidence indicates that hypoxia contributes to cancer immune suppression as well (13-16). Hypoxia, the lack of sufficient oxygen supply, is a common feature of solid tumors and aggravates the disease in different ways. Hypoxia is well-known to increase resistance to chemotherapy and radiotherapy, and to stimulate the release of angiogenic factors which induce the growth of new blood vessels (17). Tumor hypoxia also promotes epithelial-mesenchymal transition (EMT) and metastasis formation (18-21), and regulates the frequency of tumor-initiating cells (22). Hypoxic conditions activate the hypoxia-inducible factors (HIFs), the master transcription factors governing the cellular response to low oxygen tension. HIFs (mainly HIF-1 and HIF-2) are heterodimeric proteins that consist of a tightly regulated α-subunit and a constitutively expressed β-subunit. The α-subunits are rapidly degraded in normoxic conditions but are stabilized under hypoxia. Alternatively, increased HIF-1α protein and mRNA levels can be stimulated under normoxic conditions by growth factor signaling (23-25) which is frequently constitutively activated in ovarian tumors (26, 27).

Several immunosuppressive factors are direct HIF target genes such as VEGF (vascular endothelial growth factor), which exerts immunosuppressive functions in addition to its angiogenic activity (28). Hypoxia regulates the maturation and function of MDSC and constitutively activated HIF-1 in advanced tumors maintains elevated MDSC levels (29). MDSC express several enzymes involved in immunosuppression, such as indoleamine 2,3-dioxygenase-1 (IDO-1) which catalyzes the rate-limiting step of tryptophan metabolism. Up-regulation of IDO-1 inhibits T-cell activation and proliferation by tryptophan deprivation (30). MDSC also produce immunosuppressive cytokines, such as TGF-β (transforming growth factor-β) and IL-10 (interleukin-10). TGF-β together with IL-6 and IL-8 was found to frequently contribute to the establishment of the immunosuppressive environment in ovarian cancers (31).

IL-10 and TGF-β are also secreted by M2 type tumor-associated macrophages (TAM) which are attracted into hypoxic areas (32-34). In ovarian cancer, the presence of TAMs was inversely associated with relapse-free survival (35). Also T-reg cells are recruited into the hypoxic tumor through the chemokine ligand-28 (CCL28) (36). The conversion of naive into regulatory T-cells is controlled by the transcription factor FoxP3 which is up-regulated in hypoxia through HIF-1 (37). One of the FoxP3 target genes is heme oxygenase-1 (HO-1) (38) which is essential for T-reg-mediated immune suppression (39). Another transcription factor important in cancer immunosuppression is STAT-3 (40) which controls the expression of several immunosuppressive molecules and regulates the expansion and survival of MDSC (41). STAT-3 interacts with HIF-1α degradation prolonging the half-life of HIF-1α in solid tumor cells (42) suggesting that the functional interaction of STAT-3 with HIF-1 aggravates immune suppression (14).

We were interested to characterize the immunosuppressive microenvironment in ovarian cancer to evaluate the possible impact of HIFs. To address these questions, the mRNA of selected HIF target genes (cytokines, enzymes, transcription factors) were quantified in tumor tissue specimens after ovarian cancer surgery, and tumor-infiltrating leukocytes were characterized. Our analysis aimed at yielding a picture of the tolerogenic interactions between cancer cells and their immune microenvironment to visualize the immunosuppressive status and to possibly identify a ‘hypoxic signature’ in samples with elevated HIF expression. The obtained data were analyzed by statistical methods to identify sub-groups with common expression patterns and associations with clinical features.

Materials and Methods

Patient samples. Twenty-one patients with an average age of 56.1±14.1 years were included in the study. All patients had undergone primary surgery for ovarian cancer at the Clinical Department of Operative and Oncological Gynaecology, Medical University of Lodz. The study was approved by a local ethical commission and conducted according to the Helsinki declaration of ethical principles for medical research. Information about clinical parameters including staging, tumor size and ascites are shown in Table I.

Tissue processing. Immediately after surgery a small piece of tumor tissue (20-50 mm3) was submerged in RNAlater (Ambion/Life Technologies, Carlsbad, CA, USA) and transported on ice to the laboratory where it was stored at −20°C until RNA isolation. A second tissue piece of about 0.3-0.8 cm3 was put into HBSS-containing penicillin, streptavidin and fungizone and kept on ice until further processing. This tissue was minced with a scalpel and digested in HBSS/antibiotics with collagenase IV (Sigma-Aldrich, Poland) at 1 mg/ml for 1-1.5 h at 37°C. The obtained suspension was passed through a cell strainer (pore size 40 μm). Erythrocytes were lysed for one minute at room temperature in erythrocyte lysing solution (BD Biosciences/Immunogen, Chorzow, Poland). After an additional washing step in staining buffer (PBS, 1% BSA, 0.1% azide) the cell suspension was used for cell characterisation.

RNA isolation and Quantitative Reverse Transcription PCR. For RNA isolation, the specimens were manually homogenized in a lysing reagent (TriPure Isolation Reagent, Roche Diagnostics, Mannheim, Germany) and total RNA was isolated according to standard protocols. The mRNA levels of HIF-1α, HIF-2α, IL-10, VEGF-A, FoxP3, TGF-β1, HO-1, STAT-3, IDO-1 were evaluated by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) using the LC RNA amplification kit SYBR Green I, and a LightCycler Instrument 1.0 (Roche Diagnostics). The target gene expression levels were related to the house-keeping reference gene TATA-box binding protein (TBP). All primers used have been published elsewhere (43). The amplification products were analysed by the thermal dissociation method.

Cell characterization by flow cytometry. Antibodies for flow cytometry were purchased from BD Biosciences, except for APC-labelled anti-FoxP3 which was from eBioscience (Bender MedSystems, Vienna, Austria). For the characterisation of various kinds of immune suppressor cells the following combinations of directly-labelled antibodies were used: T-reg cells, CD4-CD25-FoxP3, CD3-CD8-CD28, CD8-CD28-FoxP3, and CD3-IL-10; the T-cell subset characterised by CD3-CD4-CD25 was also assessed; myeloid-derived suppressor cells (MDSC), CD11b-CD14-HLA-DR and CD11b-CD15-HLA-DR; and type 2 macrophages, CD14-CD40-CD163. Antibodies detecting CD45 were included for a clear separation of leukocytes from other cell types. B cells and NK cells were characterised by staining of CD19 and CD56, respectively. Appropriate isotype controls were included in each experiment. For intracellular stainings (FoxP3, IL-10) cells were fixed with 4% formaldehyde solution and permeabilized with 0.2% Nonidet P-40. Flow cytometric data acquisition was performed on a FACS-Calibur and CellQuest Pro was used for data analysis (BD Biosciences). Due to the limited amount of tissue each experiment was conducted only once.

Statistical analysis. The normality of the data distribution was analyzed by the Shapiro-Wilks' W-test. The relation of two sets of parameters was calculated with Spearman coefficient. Differences of the median values between two independent groups of data were calculated using the non-parametric Mann–Whitney U-test. For the cluster analysis the Euclidean distance was measured and the Ward's method was chosen as amalgamation rule. All statistical analyses were done using Statistica 10.0 software (StatSoft Inc., Tulsa, OK, USA). A value of p<0.05 was considered statistically significant.

Results

Highly variable degree and composition of tumor infiltrating leukocytes (TIL). TIL were characterized by flow cytometry. Antibody combinations were chosen for the characterisation of various kinds of T-reg cells, MDSC- and M2-type macrophages. Median values and ranges of the relative leukocyte fractions obtained in the 21 ovarian cancer samples are shown in Table II. The only suppressor cell type found in all patients was the T-reg cell subset characterized by CD3+CD8+CD28− expression. The relative numbers of TIL (CD45+) and of most cellular subsets were distributed over a wide range indicating a high variability of immune cell infiltration among the examined tumor samples.

Expression of HIF-1α, HIF-2α and their target genes. The mRNA levels of HIF-1α and HIF-2α, as well as of seven potential HIF target genes with known immunosuppressive function were assessed by one-step qRT-PCR (Table III). The mRNA expression of the transcription factors FoxP3 and STAT-3, the enzymes HO-1 and IDO-1, as well as the cytokines IL-10, VEGF-A, and TGF-β1 was measured. The results of qRT-PCR analysis were related to the house-keeping gene product TATA-box binding protein (e.g. HIF-1α/TBP) for statistical analysis. These relative expression levels are shown in Table III. The mRNA expression of most HIF target genes was detected in all samples. A relatively elevated expression of HIF-1α (>2-fold higher than the expression of the house-keeping gene) was found in about 25% of the samples.

Hierarchical clustering and correlation analysis reveals a ‘hypoxic signature’. For each patient, 18 values were assessed which characterized part of the immunosuppressive microenvironment. Pattern recognition analysis using hierarchical clustering with the combined data for mRNA expression and TIL numbers did not reveal any clearly separated subgroups. Clustering based on the mRNA expression data alone brought out a small group of samples (6 out of 21, Figure 1A) with an elevated expression of HO-1, IDO-1, IL-10, VEGF-A and STAT-3 mRNAs (Figure 1B). Also the expression levels of HIF-1α and HIF-2α were increased in this subgroup although not with statistical significance (Figure 1B). Further analysis showed that the small subgroup with relatively elevated expression of HIF target genes had a reduced number of infiltrating CD4+CD25+FoxP3+ T-reg cells (p=0.043), but a higher number of B-cells (p=0.036).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Characteristics of study patients.

The data sets obtained from the determination of TIL cell type frequencies and gene expression were analyzed pairwise. This analysis resulted in a number of significant associations as shown in Tables IV and V. For HIF-1α mRNA expression positive correlations were found with the mRNA levels of HIF-2α, Stat3, IDO-1 and VEGF-A, and with the relative number of CD8+CD28−FoxP3+ cells. HIF-2α mRNA expression correlated positively with STAT-3 mRNA levels, and STAT-3 expression was connected to IDO-1 and VEGF-A expression. The number of IL-10-expressing T-reg cells was associated with VEGF-A and IL-10 mRNA levels. More positive correlations were found between the mRNA expression values for IL-10 and HO-1, as well as IDO-1 and VEGF-A. An association of HIF-2α with VEGF-A expression was also observed but did not reach statistical significance (p=0.061).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Relative percentages of tumor-infiltrating leukocytes based on the expression of characteristic markers. The percentage of immunosuppressive cell subsets was related either to the percentage of CD45-positive cells to obtain relative leukocyte fractions, or to the total T cell (CD3-positive) fractions in case of Treg cell subsets. Percentages are given as the range and the median values.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Relative expression levels of 9 genes determined in 21 ovarian cancer samples by the ΔCt method. The ratio of the expression of the tested genes is shown in relation to TBP expression.

Several parameters determined in the clinic (including tumor grade, clinical stage, tumor size, age, etc.) (Table I) were also included in the statistical analyses (Table V). Cancer cell grading based on scores for proliferation and differentiation revealed that approximately one third of patients was grade 2, and another third was grade 3. G3 patients showed a significant higher age than patients in lower stages. Also the HIF-2α mRNA expression was higher in samples from older patients. Furthermore, the volume of ascites fluid was found to correlate with HIF-1α mRNA expression. The histological classification of ovarian cancer knows 4 major subtypes, serous (30-70%), endometrioid (10-20%), mucinous (5-20%), clear cell (3-10%), as well as undifferentiated ones (1%). Due to the relatively small number of patients involved in our study, the sample number for most subgroups was too small to be involved in any any meaningful statistical analyses. However, tumor tissues characterized as adenocarcinoma (8 out of 21 samples) showed a positive association with the expression of VEGF-A (Table V) and a reduced relative number of CD3+CD8+CD28− T-reg cells (p=0.024). The statistically significant positive correlations are schematically summarized in Figure 2.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Significant correlations were detected by pairwise association analysis of mRNA expression levels. Correlations were calculated with the Spearman coefficient.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table V.

Associations of mRNA expression levels with relative cell type numbers and clinical features. The Spearman coefficient or the Mann–Whitney U-test were employed for the calculation of the significance of the correlations.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Hierarchical tree plot based on the relative mRNA expression data. A: The results of the qRT-PCR analysis were related to the house-keeping gene product TATA-box binding protein. The resulting relative expression levels were subjected to cluster analysis using Euclidean distance as a distance measurement method. The Ward's method was chosen as amalgamation rule. B: Comparison of expression levels of HO-1, IDO-1, IL-10, VEGF-A, STAT-3, HIF-1α and HIF-2α in the two subgroups derived from the cluster analysis.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Schematic representation of positive correlations between the parameters assessed in the study. Comparison of single parameter sets (e.g. CD3+/CD8+/CD28− T-reg cells versus HIF-1α mRNA expression) was performed by Spearman coefficient analysis, while median values from defined sub-groups (e.g. VEGF mRNA expression in adenocarcinoma samples) were compared by the non-parametric Mann–Whitney U-test.

Discussion

A large number of immunosuppressive cells and factors is involved in the induction and maintenance of tolerance which is required for the establishment of malignant tumors. The components of the immune microenvironment constitute an immunoregulatory network whose actual composition may have profound influence on disease outcome (44). HIFs and STAT-3 are among the key transcription factors controlling the expression of several tolerogenic factors in the tumor tissue (16). To obtain some insight into the immune signature of individual ovarian tumors the relative amount of selected suppressor cell types and tolerogenic factors was determined together with HIF and STAT-3 mRNA expression in 21 ovarian cancer tissue samples. The tissue was preserved right at the surgery to obtain an actual picture of the cancer immune environment in the patients. mRNA degradation was kept at a minimal level by immediately submerging the excised tumor tissue in RNA-preserving solution. To avoid mRNA degradation due to tissue manipulation, gene expression was evaluated for the whole tissue as obtained from surgery without separation of specific cell types. Consequently, the cell type from which a given mRNA was derived remained unknown.

The numbers of tumor-infiltrating leukocytes showed a big variation in the analyzed samples ranging from less than 2% to more than 50% of the total cell composition. A similar broad distribution range was found for the relative numbers of single immune suppressor cell types supporting the view of a very heterogeneous immune microenvironment in ovarian cancer patients. This heterogeneity could complicate immune therapies and might contribute to low response rates. Highly variable ranges were also observed for the mRNA expression levels, although all samples expressed several HIF target genes at least to some extent. However, this observation must be qualified as the obtained relative mRNA levels were not fully-matchable between the samples, the inherent variability of the cell composition in the tumors allowed only for semi-quantitative comparisons. Bearing these limitations in mind, the relative numbers of cell types and gene expression levels were used for statistical analysis. Hierarchical clustering was employed to identify subgroups of patient samples with a common immune signature. The mRNA level clustering revealed a small group with relatively higher expression of HIF target genes with known immunosuppressive activity. These samples also showed elevated HIF-1α and HIF-2α expression demonstrating that the HIF mRNA levels correlated well with the expression of its target genes. The co-regulation of HIF activity with the mRNA levels of HIF-1α and HIF-2α was also observed in the pairwise analysis of the studied mRNA expression data. HIF activity is regulated via protein stability during changes in oxygen availability with rapid degradation of HIF proteins in normoxic conditions and stabilization in hypoxia. Alternatively, growth factor signalling via activated Ras/Mek/MAPK and PI3K/Akt/mTOR pathways can stabilize HIF proteins in normoxia (23, 24). Basically, HIF activity was measured through expression analysis of their target genes. The association of the mRNA levels of HIFs with the expression of their target genes suggests that HIF proteins are, at least partially, stabilized via growth factor signalling in ovarian cancer samples. Tumor growth beyond the diameter of 5 mm requires the establishment of blood supply. As all tumors in our study had a diameter larger than 5 cm, they had passed the phase of angiogenesis induction and intra-tumoral hypoxia was not an obligatory feature in the collected tissue specimens.

HIF-1α expression also correlated with the relative number of tumor-infiltrating T-reg cells characterized by co-expression of CD8 and FoxP3, but lacking expression of the co-stimulatory receptor CD28. This association confirmed the already described up-regulation of FoxP3 by HIF-1α (37). Not surprisingly, the accumulation of CD3+IL-10+ T-reg cells was accompanied by higher levels of IL-10 mRNA expression suggesting that these cells significantly contributed to the overall IL-10 production. Also VEGF-A was elevated in tissue samples with higher numbers of CD3+IL-10+ T-reg cells. These results are in line with a recently published study describing significant co-expression of VEGF and IL-10 assessed by immunohistochemical analysis of ovarian cancer tissue samples (45). VEGF-A mRNA expression was also relatively elevated in our samples characterized as adenocarcinomas. VEGF was suggested as an independent prognostic factor for ovarian cancer and high levels in plasma or ascites fluid inversely correlate with survival (46). Furthermore, VEGF was shown to induce ascites by increasing the peritoneal permeability (47). We found a positive association between HIF-1α mRNA expression and the volume of ascites fluid. As VEGF is one of the major target genes of HIF-1α our results suggest that HIF1α mediates ascites accumulation through VEGF production. Two parameters were found to be associated with older age, namely high grade cancers (G3) and HIF-2α mRNA expression. A similar connection of cancer grade and age has been observed previously (48). In conclusion, the association of HIF mRNA expression with the mRNA levels of HIF target genes suggests that in ovarian cancer HIF activity is at least partially upregulated by growth factor signalling. Nuclear expression of HIF-1α was suggested as independent prognostic factor for ovarian cancer (49). Relatively elevated expression levels of several HIF target genes exerting immunosuppressive functions was observed in about one quarter of the examined samples indicating a subgroup of patients in which targeting HIF might be considered to weaken cancer immunosuppression.

Acknowledgements

This work was supported by the Grant no. N402 458738 from the Ministry of Science and Higher Education (Poland).

Footnotes

  • Conflicts of Interest

    The Authors declare that they have no conflicts of interest.

  • Received February 18, 2014.
  • Revision received March 28, 2014.
  • Accepted March 31, 2014.
  • Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Jemal A,
    2. Siegel R,
    3. Xu J,
    4. Ward E
    : Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Marsh S,
    2. Jim P,
    3. King CR,
    4. Gifford G,
    5. McLeod HL,
    6. Brown R
    : Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer. The Scotish Randomised Trial in Ovarian Cancer. J Clin Oncol 25: 4528-4535, 2007.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Wilczyński JR,
    2. Duechler M
    : How do tumors actively escape from host immunosurveillance? Arch Immunol Ther Exp (Warsz) 58: 435-448, 2010.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Scarlett UK,
    2. Rutkowski MR,
    3. Rauwerdink AM,
    4. Fields J,
    5. Escovar-Fadul X,
    6. Baird J,
    7. Cubillos-Ruiz JR,
    8. Jacobs AC,
    9. Gonzalez JL,
    10. Weaver J,
    11. Fiering S,
    12. Conejo-Garcia JR
    : Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 209: 495-506, 2012.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Cubillos-Ruiz JR,
    2. Rutkowski M,
    3. Conejo-Garcia JR
    : Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle 9: 260-268, 2010.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Lavoué V,
    2. Thédrez A,
    3. Levêque J,
    4. Foucher F,
    5. Henno S,
    6. Jauffret V,
    7. Belaud-Rotureau MA,
    8. Catros V,
    9. Cabillic F
    : Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med 11: 147-158, 2013.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Ohara M,
    2. Yamaguchi Y,
    3. Matsuura K,
    4. Murakami S,
    5. Arihiro K,
    6. Okada M
    : Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer. Cancer Immunol Immunother 58: 441-447, 2009.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Curiel TJ,
    2. Coukos G,
    3. Zou L,
    4. Alvarez X,
    5. Cheng P,
    6. Mottram P,
    7. Evdemon-Hogan M,
    8. Conejo-Garcia JR,
    9. Zhang L,
    10. Burow M,
    11. Zhu Y,
    12. Wei S,
    13. Kryczek I,
    14. Daniel B,
    15. Gordon A,
    16. Myers L,
    17. Lackner A,
    18. Disis ML,
    19. Knutson KL,
    20. Chen L,
    21. Zou W
    : Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med 10: 942-949, 2004.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Wolf D,
    2. Wolf AM,
    3. Rumpold H,
    4. Fiegl H,
    5. Zeimet AG,
    6. Muller-Holzner E,
    7. Deibl M,
    8. Gastl G,
    9. Gunsilius E,
    10. Marth C
    : The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11: 8326-8331, 2005.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Gabrilovich DI,
    2. Nagaraj S
    : Myeloid-derived suppressor cells as regulators of the immune system. Nature Rev Immunol 9: 162-174, 2009.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Gabrilovich DI,
    2. Ostrand-Rosenberg S,
    3. Bronte V
    : Coordinated regulation of myeloid cells by tumors. Nature Rev Immunol 12: 253-268, 2012.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Siveen KS,
    2. Kuttan G
    : Role of macrophages in tumour progression. Immunol Lett 123: 97-102, 2009.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Lee CT,
    2. Mace T,
    3. Repasky EA
    : Hypoxia-Driven Immunosuppression: A new reason to use thermal therapy in the treatment of cancer? Int J Hyperthermia 26: 232-246, 2010.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Wei J,
    2. Wu A,
    3. Kong LY,
    4. Wang Y,
    5. Fuller G,
    6. Fokt I,
    7. Melillo G,
    8. Priebe W,
    9. Heimberger AB
    : Hypoxia potentiates glioma-mediated immunosuppression. PLoS One 6: e16195, 2011.
    OpenUrlCrossRefPubMed
    1. Chouaib S,
    2. Messai Y,
    3. Couve S,
    4. Escudier B,
    5. Hasmim M,
    6. Noman MZ
    : Hypoxia promotes tumour growth in linking angiogenesis to immune escape. Front Immunol 3: 21-30, 2012.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Duechler M,
    2. Wilczynski JR
    : Hypoxia Inducible Factor-1 in Cancer Immune Suppression. Curr Immunol Rev 6: 260-271, 2010.
    OpenUrl
  16. ↵
    1. Semenza GL
    : Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33: 207-214, 2012.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Kizaka-Kondoh S,
    2. Inoue M,
    3. Harada H,
    4. Hiraoka M
    : Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 94: 1021-1028, 2003.
    OpenUrlCrossRefPubMed
    1. Weilbaecher KN,
    2. Guise TA,
    3. McCauley LK
    : Cancer to bone: a fatal attraction. Nature Rev Cancer 11: 411-425, 2011.
    OpenUrlCrossRefPubMed
    1. Chaturvedi P,
    2. Gilkes DM,
    3. Wong CC,
    4. Kshitiz,
    5. Luo W,
    6. Zhang H,
    7. Wei H,
    8. Takano N,
    9. Schito L,
    10. Levchenko A,
    11. Semenza GL
    : Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. J Clin Invest 123: 189-205, 2013.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Cheng JC,
    2. Klausen C,
    3. Leung PC
    : Hypoxia-inducible factor 1 alpha mediates epidermal growth factor-induced down-regulation of E-cadherin expression and cell invasion in human ovarian cancer cells. Cancer Lett 329: 197-206, 2013.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Schwab LP,
    2. Peacock DL,
    3. Majumdar D,
    4. Ingels JF,
    5. Jensen LC,
    6. Smith KD,
    7. Cushing RC,
    8. Seagroves TN
    : Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res 14: R6, 2012.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Bilton RL,
    2. Booker GW
    : The subtle side to hypoxia inducible factor (HIFalpha) regulation. Eur J Biochem 270: 791-798, 2003.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Doe MR,
    2. Ascano JM,
    3. Kaur M,
    4. Cole MD
    : Myc posttranscriptionally induces HIF1 protein and target gene expression in normal and cancer cells. Cancer Res 72: 949-957, 2012.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Bian CX,
    2. Shi Z,
    3. Meng Q,
    4. Jiang Y,
    5. Liu LZ,
    6. Jiang BH
    : P70S6K1 regulation of angiogenesis through VEGF and HIF-1alpha expression. Biochem Biophys Res Commun 398: 395-399, 2010.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Altomare DA,
    2. Wang HQ,
    3. Skele KL,
    4. De Rienzo A,
    5. Klein-Szanto AJ,
    6. Godwin AK,
    7. Testa JR
    : AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23: 5853-5857, 2004.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Steinmetz R,
    2. Wagoner HA,
    3. Zeng P,
    4. Hammond JR,
    5. Hannon TS,
    6. Meyers JL,
    7. Pescovitz OH
    : Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation. Mol Endocrinol 18: 2570-2582, 2004.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Gavalas NG,
    2. Tsiatas M,
    3. Tsitsilonis O,
    4. Politi E,
    5. Ioannou K,
    6. Ziogas AC,
    7. Rodolakis A,
    8. Vlahos G,
    9. Thomakos N,
    10. Haidopoulos D,
    11. Terpos E,
    12. Antsaklis A,
    13. Dimopoulos MA,
    14. Bamias A
    : VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. British J Cancer 107: 1869-1875, 2012.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Corzo CA,
    2. Condamine T,
    3. Lu L,
    4. Cotter MJ,
    5. Youn JI,
    6. Cheng P,
    7. Cho HI,
    8. Celis E,
    9. Quiceno DG,
    10. Padhya T,
    11. McCaffrey TV,
    12. McCaffrey JC,
    13. Gabrilovich DI
    : Hif-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumour microenvironment. J Exp Med 207: 2439-2453, 2010.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Hill M,
    2. Tanguy-Royer S,
    3. Royer P,
    4. Chauveau C,
    5. Asghar K,
    6. Tesson L,
    7. Lavainne F,
    8. Rémy S,
    9. Brion R,
    10. Hubert FX,
    11. Heslan M,
    12. Rimbert M,
    13. Berthelot L,
    14. Moffett JR,
    15. Josien R,
    16. Grégoire M,
    17. Anegon I
    : IDO expands human CD4+CD25 high regulatory cells by promoting maturation of LPS-treated dendritic cells. Eur J Immunol 37: 3054-3062, 2007.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Toutirais O,
    2. Chartier P,
    3. Dubois D,
    4. Bouet F,
    5. Lévêque J,
    6. Catros-Quemener V,
    7. Genetet N
    : Constitutive expression of TGF-beta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. Eur Cytokine Netw 14: 246-255, 2003.
    OpenUrlPubMed
  29. ↵
    1. Murdoch C,
    2. Giannoudis A,
    3. Lewis CE
    : Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumours and other ischemic tissues. Blood 104: 2224-2234, 2004.
    OpenUrlAbstract/FREE Full Text
    1. Lewis CE,
    2. Pollard JW
    : Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605-612, 2006.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Nardin A,
    2. Abastado JP
    : Macrophages and cancer. Front Biosci 13: 3494-3505, 2008.
    OpenUrlPubMed
  31. ↵
    1. Reinartz S,
    2. Schumann T,
    3. Finkernagel F,
    4. Wortmann A,
    5. Jansen JM,
    6. Meissner W,
    7. Krause M,
    8. Schwörer AM,
    9. Wagner U,
    10. Müller-Brüsselbach S,
    11. Müller R
    : Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: Correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer 134: 32-42, 2014.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Facciabene A,
    2. Peng X,
    3. Hagemann IS,
    4. Balint K,
    5. Barchetti A,
    6. Wang LP,
    7. Gimotty PA,
    8. Gilks CB,
    9. Lal P,
    10. Zhang L,
    11. Coukos G
    : Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475: 226-230, 2011.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Ben-Shoshan J,
    2. Maysel-Auslender S,
    3. Mor A,
    4. Keren G,
    5. George J
    : Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur J Immunol 38: 2412-2418, 2008.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Choi BM,
    2. Pae HO,
    3. Jeong YR,
    4. Kim YM,
    5. Chung HT
    : Critical role of heme oxygenase-1 in Foxp3-mediated immune suppression. Biochem Biophys Res Commun 327: 1066-1071, 2005.
    OpenUrlCrossRefPubMed
  35. ↵
    1. El Andaloussi A,
    2. Lesniak MS
    : CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumour grade in human gliomas. J Neurooncol 83: 145-152, 2007.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Kanterman J,
    2. Sade-Feldman M,
    3. Baniyash M
    : New insights into chronic inflammation-induced immunosuppression. Sem Cancer Biol 22: 307-318, 2012.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Poschke I,
    2. Mougiakakos D,
    3. Hansson J,
    4. Masucci GV,
    5. Kiessling R
    : Immature immunosuppressive CD14+HLA-DR- /low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 70: 4335-4345, 2010.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Jung JE,
    2. Kim HS,
    3. Lee CS,
    4. Shin YJ,
    5. Kim YN,
    6. Kang GH,
    7. Kim TY,
    8. Juhnn YS,
    9. Kim SJ,
    10. Park JW,
    11. Ye SK,
    12. Chung MH
    : STAT3 inhibits the degradation of Hif-1α by pVHL-mediated Ubiquitination. Exp Mol Med 40: 479-485, 2008.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Duechler M,
    2. Peczek L,
    3. Zuk K,
    4. Zalesna I,
    5. Jeziorski A,
    6. Czyz M
    : The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes. Immunobiology 219: 158-165, 2014.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Fridman WH,
    2. Pagès F,
    3. Sautès-Fridman C,
    4. Galon J
    : The immune contexture in human tumours: impact on clinical outcome. Nature Rev Cancer 12: 298-306, 2012.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Liu CZ,
    2. Zhang L,
    3. Chang XH,
    4. Cheng YX,
    5. Cheng HY,
    6. Ye X,
    7. Fu TY,
    8. Chen J,
    9. Cui H
    : Overexpression and Immunosuppressive Functions of Transforming Growth Factor β1, Vascular Endothelial Growth Factor and Interleukin-10 in Epithelial Ovarian Cancer. Chin J Cancer Res 24: 130-137, 2012.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Masoumi-haddam S,
    2. Amini A,
    3. Morris DL,
    4. Pourgholami MH
    : Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev 31: 143-162, 2012.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Herr D,
    2. Sallmann A,
    3. Bekes I,
    4. Konrad R,
    5. Holzheu I,
    6. Kreienberg R,
    7. Wulff C
    : VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5. Gynecol Oncol 127: 210-216, 2012.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Giuliani J,
    2. Drudi F
    : Ovarian cancer in elderly patients: a difference in treatment based on age? Arch Gynecol Obstet 286: 1545-1548, 2012.
    OpenUrlPubMed
  45. ↵
    1. Osada R,
    2. Horiuchi A,
    3. Kikuchi N,
    4. Yoshida J,
    5. Hayashi A,
    6. Ota M,
    7. Katsuyama Y,
    8. Melillo G,
    9. Konishi I
    : Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum Pathol 38: 1310-1320, 2007.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 34, Issue 6
June 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Influence of Hypoxia Inducible Factors on the Immune Microenvironment in Ovarian Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 12 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Influence of Hypoxia Inducible Factors on the Immune Microenvironment in Ovarian Cancer
MARKUS DUECHLER, LUKASZ PECZEK, MARIA SZUBERT, JACEK SUZIN
Anticancer Research Jun 2014, 34 (6) 2811-2819;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Influence of Hypoxia Inducible Factors on the Immune Microenvironment in Ovarian Cancer
MARKUS DUECHLER, LUKASZ PECZEK, MARIA SZUBERT, JACEK SUZIN
Anticancer Research Jun 2014, 34 (6) 2811-2819;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Recapitulating physiologically relevant oxygen levels and extracellular matrix remodeling in patient-derived tumor-immune tunable models reveal targeting opportunities for immunologically cold high-grade serous tumors
  • Google Scholar

More in this TOC Section

  • Low-dose Andrographolide Synergizes With Cytarabine or Vincristine in Plasma Cell Neoplasm Cell Lines
  • Enzalutamide Enhanced Honokiol-induced Apoptotic Insults to Drug-resistant Glioblastoma Cells via an Intrinsic Bak-mitochondrion-caspase Cascade Mechanism
  • Milk Extracellular Vesicle–mediated Delivery of siPRNP Suppresses Growth and Wound Closure in PC-3M Prostate Cancer Cells
Show more Experimental Studies

Keywords

  • Cancer immunosuppression
  • cancer hypoxia
  • human ovarian cancer
  • immune microenvironment
  • surgical specimen
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire